A cheap vial is only cheap per vial. What you are buying is milligrams of the right peptide, and the price does not show three things that decide how many you get: purity, how much is actually in the vial, and whether the molecule is the one on the label. Each can be measured, and each costs money to get right.
A listing invites one comparison: this vial against that one, price against price. It is the wrong comparison, because the vial is a container. What decides value is how many milligrams of the intended peptide are inside it, and the sticker shows none of the three numbers that determine that.
The first is purity: the share of the peptide material that is the target sequence rather than shortened or incomplete versions of it. The second is content: how many milligrams are in the glass, which depends on how accurately the vial was filled and on how much of the powder is peptide at all rather than salt and water. The third is identity: whether the molecule is the one on the label. A vial can be pure, full and the wrong peptide.
Purity and content multiply. A vial labelled 10mg at 70% purity holds 7mg of peptide. If it is also underfilled and assays at 8.4mg, it holds 5.88mg. The label still says 10mg and the price is unchanged.
Divide what you paid by the milligrams of peptide actually present. The four vials below are illustrative, not any seller's products, and they are the same examples the purity-adjusted cost calculator uses.
| Vial | Price | Label | Purity | Measured content | Real peptide | Per real mg |
|---|---|---|---|---|---|---|
| A | $60 | 10mg | 70% | 10mg | 7.00mg | $8.57 |
| A, underfilled | $60 | 10mg | 70% | 8.4mg | 5.88mg | $10.20 |
| B | $160 | 15mg | 99% | 15mg | 14.85mg | $10.77 |
| C | $80 | 10mg | 98% | 10mg | 9.80mg | $8.16 |
The cheap vial wins against the dearer one on its stated figures — $8.57 against $10.77 per real milligram. It loses as soon as it is underfilled, at $10.20. And a vial that is cheap and genuinely pure, like the third, beats both. The arithmetic does not always favour the higher price, and it should not. What it rules out is comparing on sticker price and calling the difference a saving.
Every one of those results depends on the inputs being true. A purity figure with no certificate behind it is not 99% or 70%; it is unknown, and the calculation cannot be run. Treating unknown as 99% is the assumption that makes a cheap vial look cheap.
Research peptides are built by solid-phase synthesis, one amino acid at a time, each coupled onto the growing chain. No step is perfect, and the losses compound: the share of chains that end up complete is the per-step efficiency raised to the number of steps.
| Peptide length | 99% per step | 98% per step |
|---|---|---|
| 15 residues (e.g. BPC-157) | 86.0% | 73.9% |
| 39 residues (e.g. tirzepatide) | 67.6% | 45.5% |
At 99% per step, a 15-residue peptide such as BPC-157 comes off the resin about 86% complete; a 39-residue peptide such as tirzepatide, about 68%. At 98% per step those fall to about 74% and 45%. The rest is deletion and truncated sequences — chains missing one residue or stopped short — which are chemically close to the target and have to be separated from it.
That separation is preparative HPLC, and it is where purity is bought. Reaching 98% or better means cutting the collected fractions tightly and discarding material that is mostly right, so the yield of finished peptide from each synthesis falls as the purity specification rises. A seller who stops purifying earlier gets more grams from the same synthesis, and can price accordingly. The vial will still look the same: a white cake of lyophilised powder.
Purity by HPLC answers one question: of the peptide-related material, how much is the target sequence. It does not say how much of the powder is peptide. Peptides purified by reversed-phase HPLC usually leave the column as trifluoroacetate salts, because trifluoroacetic acid is in the mobile phase, and lyophilised peptides take up water from the air. Both add weight that is not peptide.
That is why net peptide content is a separate measurement from purity, and why a vial can be 99% pure and still hold less peptide than its label. Exchanging the counter-ion for acetate or chloride is an extra processing step, and measuring water content is an extra test. Both are easy to leave out.
A batch that is properly released needs at least three measurements. HPLC gives purity. Mass spectrometry confirms identity, which HPLC cannot: a trace can read 99% on the wrong peptide. And a heavy-metal screen — lead, mercury, arsenic and cadmium, each with a figure and a unit — checks for contamination that neither of the first two would reveal.
Those costs are per batch, not per vial. They are the same whether the batch fills a hundred vials or ten thousand, which makes them expensive per vial on small batches and invisible on the price tag either way. They are also the easiest saving available, because a buyer cannot see whether they were done. A certificate that names the batch, the method and the date is the only evidence that they were.
Two peer-reviewed studies bought injectable peptide products from online sources operating outside regulated supply and tested them. Neither names, or tells you anything about, any particular seller's vial.
A Belgian study of the ten falsified peptide drugs most often encountered on that market, bought from suspected illegal internet pharmacies, found high variation in the amount of drug per unit and low purity — 5% to 75% for the cysteine-containing peptides — along with arsenic and lead, some samples above the international limits for injectable products by up to tenfold.
A 2024 study ordered semaglutide from six websites selling it without a prescription. Three never delivered. In the three that arrived, semaglutide was present but at 7% to 14% purity against an advertised 99%, the measured content exceeded the label by 29% to 39%, and one sample carried an elevated endotoxin level.
The point is not that every inexpensive vial resembles these. It is that a label and a price, on their own, are not evidence of what is in the vial — in either direction.
Some of it is legitimate. Very large production runs spread fixed costs thinly, and a seller with low overheads can price below one with high ones. None of that reduces what is in the vial.
The rest comes from the steps a buyer cannot see: purifying less, so more of each synthesis is sold; skipping identity confirmation, so a near-miss sequence goes out under the right name; skipping the metals screen; filling by volume rather than weight; leaving the peptide as a trifluoroacetate salt. Each makes the vial cheaper to produce and none changes how it looks.
That is why the only useful question about a low price is what the certificate behind it says, and whether that certificate belongs to the batch in your hand.
Ask for the certificate of analysis for the batch you would receive, not a sample one. Check that it names the batch, the date, the method behind the purity figure and a laboratory, and that it confirms identity by mass spectrometry. The certificate checker on this site lists what a complete one contains.
Then convert both prices into cost per milligram of real peptide using the purity and content on those certificates. The purity-adjusted cost calculator does the arithmetic. If one seller cannot supply the inputs, that is the answer to the comparison.
We make our peptides in our own laboratory in Australia. Every batch is tested here before release — HPLC purity of 99% or better, identity by mass spectrometry and a screen for lead, mercury, arsenic and cadmium — and the results are recorded against the batch number on the vial. Our prices carry that work.
Partly scale, and partly the work a buyer cannot see: less purification, no identity test, no heavy-metal screen, approximate filling. Each lowers the cost of a vial without changing how it looks, so the price alone cannot tell you which applies.
No. A cheap vial that is genuinely pure and correctly filled costs less per milligram and is the better buy. The point is to compare cost per milligram of real peptide, using figures a certificate stands behind, rather than price per vial.
What you paid divided by the milligrams of peptide actually present: measured content multiplied by purity. A $60 vial labelled 10mg at 70% purity holds 7mg, which is $8.57 per milligram.
Because synthesis losses compound with every residue added, and the incomplete chains have to be removed by preparative HPLC. Tighter purity means discarding more material, so each synthesis yields fewer grams of finished peptide.
A peptide chain missing one or more residues because a coupling step failed. It is chemically close to the target, which is why it survives into crude product and has to be separated out.
The share of a lyophilised powder that is peptide, as opposed to counter-ion salt and water. It is measured separately from HPLC purity, which only describes the peptide-related material.
Yes. HPLC measures how much of the sample is one species, not which species it is. Identity is confirmed by mass spectrometry, which is why a complete certificate reports both.
No. It means a label and a price are not evidence either way. The published studies tested products from unregulated online sources and found serious problems, but they say nothing about any particular vial. Only a batch-matched certificate does.
This guide is for educational purposes and is not medical advice. OzPeptides products are sold for research and laboratory use only, not for human consumption. 18+ only.